{"pmid":32486488,"title":"Nicotinamide Riboside-The Current State of Research and Therapeutic Uses.","text":["Nicotinamide Riboside-The Current State of Research and Therapeutic Uses.","Nicotinamide riboside (NR) has recently become one of the most studied nicotinamide adenine dinucleotide (NAD(+)) precursors, due to its numerous potential health benefits mediated via elevated NAD(+) content in the body. NAD(+) is an essential coenzyme that plays important roles in various metabolic pathways and increasing its overall content has been confirmed as a valuable strategy for treating a wide variety of pathophysiological conditions. Accumulating evidence on NRs' health benefits has validated its efficiency across numerous animal and human studies for the treatment of a number of cardiovascular, neurodegenerative, and metabolic disorders. As the prevalence and morbidity of these conditions increases in modern society, the great necessity has arisen for a rapid translation of NR to therapeutic use and further establishment of its availability as a nutritional supplement. Here, we summarize currently available data on NR effects on metabolism, and several neurodegenerative and cardiovascular disorders, through to its application as a treatment for specific pathophysiological conditions. In addition, we have reviewed newly published research on the application of NR as a potential therapy against infections with several pathogens, including SARS-CoV-2. Additionally, to support rapid NR translation to therapeutics, the challenges related to its bioavailability and safety are addressed, together with the advantages of NR to other NAD(+) precursors.","Nutrients","Mehmel, Mario","Jovanovic, Nina","Spitz, Urs","32486488"],"abstract":["Nicotinamide riboside (NR) has recently become one of the most studied nicotinamide adenine dinucleotide (NAD(+)) precursors, due to its numerous potential health benefits mediated via elevated NAD(+) content in the body. NAD(+) is an essential coenzyme that plays important roles in various metabolic pathways and increasing its overall content has been confirmed as a valuable strategy for treating a wide variety of pathophysiological conditions. Accumulating evidence on NRs' health benefits has validated its efficiency across numerous animal and human studies for the treatment of a number of cardiovascular, neurodegenerative, and metabolic disorders. As the prevalence and morbidity of these conditions increases in modern society, the great necessity has arisen for a rapid translation of NR to therapeutic use and further establishment of its availability as a nutritional supplement. Here, we summarize currently available data on NR effects on metabolism, and several neurodegenerative and cardiovascular disorders, through to its application as a treatment for specific pathophysiological conditions. In addition, we have reviewed newly published research on the application of NR as a potential therapy against infections with several pathogens, including SARS-CoV-2. Additionally, to support rapid NR translation to therapeutics, the challenges related to its bioavailability and safety are addressed, together with the advantages of NR to other NAD(+) precursors."],"journal":"Nutrients","authors":["Mehmel, Mario","Jovanovic, Nina","Spitz, Urs"],"date":"2020-06-04T11:00:00Z","year":2020,"_id":"32486488","source":"PubMed","week":"202023|Jun 01 - Jun 07","doi":"10.3390/nu12061616","keywords":["covid-19","age-associated diseases","bioavailability","metabolic disorders","nicotinamide adenine dinucleotide","nicotinamide riboside","safety","supplementation"],"e_drugs":["NAD","nicotinamide-beta-riboside"],"topics":["Treatment","Mechanism"],"weight":1,"_version_":1668623433757360129,"score":9.490897,"similar":[{"pmid":32404899,"title":"Clinical significance of nutritional risk screening for older adult patients with COVID-19.","text":["Clinical significance of nutritional risk screening for older adult patients with COVID-19.","OBJECTIVES: The aim of this study was to assess the nutritional risks among older patients with COVID-19 and their associated clinical outcomes using four nutritional risk screening (NRS) tools: Nutrition Risk Screening 2002 (NRS 2002), Malnutrition Universal Screening Tool (MUST), Mini Nutrition Assessment Shortcut (MNA-sf), and Nutrition Risk Index (NRI). METHODS: We retrospectively analyzed the data of patients with COVID-19 older than 65 years who were treated in our hospital from January 28, 2020 to March 5, 2020, and explored the relationship between nutritional risk and clinical outcomes. RESULTS: A total of 141 patients with COVID-19 (46 common COVID-19, 73 severe COVID-19, and 22 extremely severe COVID-19) were enrolled in the study. NRS 2002 identified 85.8% of patients as having risk, with being identified 41.1% by MUST, 77.3% by MNA-sf, and 71.6% by NRI. The agreement strength was moderate between NRS 2002 and MNA-sf, NRI, fair between MUST and MNA-sf, NRI, fair between MNA-sf and NRI, poor between NRS 2002 and MUST (P < 0.01). After adjustment for confounding factors in multivariate regression analysis, patients in the risk group had significantly longer LOS, higher hospital expenses (except MNA-sf), poor appetite, heavier disease severity, and more weight change(kg) than normal patients by using NRS 2002, MNA-sf, and NRI(P < 0.05). CONCLUSIONS: The NRS 2002, MNA-sf, and NRI are useful and practical tools with respect to screening for patients with COVID-19 who are at nutritional risk, as well as in need of additional nutritional intervention.","Eur J Clin Nutr","Liu, Gaoli","Zhang, Shaowen","Mao, Zhangfan","Wang, Weixing","Hu, Haifeng","32404899"],"abstract":["OBJECTIVES: The aim of this study was to assess the nutritional risks among older patients with COVID-19 and their associated clinical outcomes using four nutritional risk screening (NRS) tools: Nutrition Risk Screening 2002 (NRS 2002), Malnutrition Universal Screening Tool (MUST), Mini Nutrition Assessment Shortcut (MNA-sf), and Nutrition Risk Index (NRI). METHODS: We retrospectively analyzed the data of patients with COVID-19 older than 65 years who were treated in our hospital from January 28, 2020 to March 5, 2020, and explored the relationship between nutritional risk and clinical outcomes. RESULTS: A total of 141 patients with COVID-19 (46 common COVID-19, 73 severe COVID-19, and 22 extremely severe COVID-19) were enrolled in the study. NRS 2002 identified 85.8% of patients as having risk, with being identified 41.1% by MUST, 77.3% by MNA-sf, and 71.6% by NRI. The agreement strength was moderate between NRS 2002 and MNA-sf, NRI, fair between MUST and MNA-sf, NRI, fair between MNA-sf and NRI, poor between NRS 2002 and MUST (P < 0.01). After adjustment for confounding factors in multivariate regression analysis, patients in the risk group had significantly longer LOS, higher hospital expenses (except MNA-sf), poor appetite, heavier disease severity, and more weight change(kg) than normal patients by using NRS 2002, MNA-sf, and NRI(P < 0.05). CONCLUSIONS: The NRS 2002, MNA-sf, and NRI are useful and practical tools with respect to screening for patients with COVID-19 who are at nutritional risk, as well as in need of additional nutritional intervention."],"journal":"Eur J Clin Nutr","authors":["Liu, Gaoli","Zhang, Shaowen","Mao, Zhangfan","Wang, Weixing","Hu, Haifeng"],"date":"2020-05-15T11:00:00Z","year":2020,"_id":"32404899","source":"PubMed","week":"202020|May 11 - May 17","doi":"10.1038/s41430-020-0659-7","topics":["Prevention"],"weight":1,"_version_":1666802845574234112,"score":349.10922},{"pmid":32327922,"pmcid":"PMC7163231","title":"The 4 D's of Pellagra and Progress.","text":["The 4 D's of Pellagra and Progress.","Nicotinamide homeostasis is a candidate common denominator to explain smooth transitions, whether demographic, epidemiological or economic. This 'NAD world', dependent on hydrogen-based energy, is not widely recognised as it is neither measured nor viewed from a sufficiently multi-genomic or historical perspective. Reviewing the importance of meat and nicotinamide balances during our co-evolution, recent history suggests that populations only modernise and age well with low fertility on a suitably balanced diet. Imbalances on the low meat side lead to an excess of infectious disease, short lives and boom-bust demographics. On the high side, meat has led to an excess of degenerative, allergic and metabolic disease and low fertility. A 'Goldilocks' diet derived from mixed and sustainable farming (preserving the topsoil) allows for high intellectual capital, height and good health with controlled population growth resulting in economic growth and prosperity. Implementing meat equity worldwide could lead to progress for future generations on 'spaceship' earth by establishing control over population quality, thermostat and biodiversity, if it is not already too late.","Int J Tryptophan Res","Williams, Adrian C","Hill, Lisa J","32327922"],"abstract":["Nicotinamide homeostasis is a candidate common denominator to explain smooth transitions, whether demographic, epidemiological or economic. This 'NAD world', dependent on hydrogen-based energy, is not widely recognised as it is neither measured nor viewed from a sufficiently multi-genomic or historical perspective. Reviewing the importance of meat and nicotinamide balances during our co-evolution, recent history suggests that populations only modernise and age well with low fertility on a suitably balanced diet. Imbalances on the low meat side lead to an excess of infectious disease, short lives and boom-bust demographics. On the high side, meat has led to an excess of degenerative, allergic and metabolic disease and low fertility. A 'Goldilocks' diet derived from mixed and sustainable farming (preserving the topsoil) allows for high intellectual capital, height and good health with controlled population growth resulting in economic growth and prosperity. Implementing meat equity worldwide could lead to progress for future generations on 'spaceship' earth by establishing control over population quality, thermostat and biodiversity, if it is not already too late."],"journal":"Int J Tryptophan Res","authors":["Williams, Adrian C","Hill, Lisa J"],"date":"2020-04-25T11:00:00Z","year":2020,"_id":"32327922","source":"PubMed","week":"202017|Apr 20 - Apr 26","doi":"10.1177/1178646920910159","keywords":["co2 emissions","covid-19","climate change","nad worlds","parkinson disease","anthropocene","coronavirus","deaths of despair","demographic transition","disease x","disease transitions","meat","metabolic rift","new levellers","nicotinamide","protonopathy"],"e_drugs":["Niacinamide"],"weight":0,"_version_":1666138494755405824,"score":265.38226},{"pmid":32276196,"pmcid":"PMC7195354","title":"Psychological status of medical workforce during the COVID-19 pandemic: A cross-sectional study.","text":["Psychological status of medical workforce during the COVID-19 pandemic: A cross-sectional study.","The pandemic of 2019 coronavirus disease (COVID-19) has burdened an unprecedented psychological stress on people around the world, especially the medical workforce. The study focuses on assess the psychological status of them. The authors conducted a single-center, cross-sectional survey via online questionnaires. Occurrence of fear, anxiety and depression were measured by the numeric rating scale (NRS) on fear, Hamilton Anxiety Scale (HAMA), and Hamilton Depression Scale (HAMD), respectively. A total of 2299 eligible participants were enrolled from the authors' institution, including 2042 medical staff and 257 administrative staff. The severity of fear, anxiety and depression were significantly different between two groups. Furthermore, as compared to the non-clinical staff, front line medical staff with close contact with infected patients, including working in the departments of respiratory, emergency, infectious disease, and ICU, showed higher scores on fear scale, HAMA and HAMD, and they were 1.4 times more likely to feel fear, twice more likely to suffer anxiety and depression. The medical staff especially working in above-mentioned departments made them more susceptible to psychological disorders. Effective strategies toward to improving the mental health should be provided to these individuals.","Psychiatry Res","Lu, Wen","Wang, Hang","Lin, Yuxing","Li, Li","32276196"],"abstract":["The pandemic of 2019 coronavirus disease (COVID-19) has burdened an unprecedented psychological stress on people around the world, especially the medical workforce. The study focuses on assess the psychological status of them. The authors conducted a single-center, cross-sectional survey via online questionnaires. Occurrence of fear, anxiety and depression were measured by the numeric rating scale (NRS) on fear, Hamilton Anxiety Scale (HAMA), and Hamilton Depression Scale (HAMD), respectively. A total of 2299 eligible participants were enrolled from the authors' institution, including 2042 medical staff and 257 administrative staff. The severity of fear, anxiety and depression were significantly different between two groups. Furthermore, as compared to the non-clinical staff, front line medical staff with close contact with infected patients, including working in the departments of respiratory, emergency, infectious disease, and ICU, showed higher scores on fear scale, HAMA and HAMD, and they were 1.4 times more likely to feel fear, twice more likely to suffer anxiety and depression. The medical staff especially working in above-mentioned departments made them more susceptible to psychological disorders. Effective strategies toward to improving the mental health should be provided to these individuals."],"journal":"Psychiatry Res","authors":["Lu, Wen","Wang, Hang","Lin, Yuxing","Li, Li"],"date":"2020-04-11T11:00:00Z","year":2020,"_id":"32276196","source":"PubMed","week":"202015|Apr 06 - Apr 12","doi":"10.1016/j.psychres.2020.112936","keywords":["anxiety","coronavirus pneumonia","depression","fear","medical staff"],"weight":0,"_version_":1666138491730264064,"score":210.83951},{"pmid":32294562,"pmcid":"PMC7152904","title":"A search for medications to treat COVID-19 via in silico molecular docking models of the SARS-CoV-2 spike glycoprotein and 3CL protease.","text":["A search for medications to treat COVID-19 via in silico molecular docking models of the SARS-CoV-2 spike glycoprotein and 3CL protease.","BACKGROUND: The COVID-19 has now been declared a global pandemic by the World Health Organization. There is an emergent need to search for possible medications. METHOD: Utilization of the available sequence information, homology modeling, and in slico docking a number of available medications might prove to be effective in inhibiting the SARS-CoV-2 two main drug targets, the spike glycoprotein, and the 3CL protease. RESULTS: Several compounds were determined from the in silico docking models that might prove to be effective inhibitors for SARS-CoV-2. Several antiviral medications: Zanamivir, Indinavir, Saquinavir, and Remdesivir show potential as and 3CL(PRO) main proteinase inhibitors and as a treatment for COVID-19. CONCLUSION: Zanamivir, Indinavir, Saquinavir, and Remdesivir are among the exciting hits on the 3CL(PRO) main proteinase. It is also exciting to uncover that Flavin Adenine Dinucleotide (FAD) Adeflavin, B2 deficiency medicine, and Coenzyme A, a coenzyme, may also be potentially used for the treatment of SARS-CoV-2 infections. The use of these off-label medications may be beneficial in the treatment of the COVID-19.","Travel Med Infect Dis","Hall, Donald C Jr","Ji, Hai-Feng","32294562"],"abstract":["BACKGROUND: The COVID-19 has now been declared a global pandemic by the World Health Organization. There is an emergent need to search for possible medications. METHOD: Utilization of the available sequence information, homology modeling, and in slico docking a number of available medications might prove to be effective in inhibiting the SARS-CoV-2 two main drug targets, the spike glycoprotein, and the 3CL protease. RESULTS: Several compounds were determined from the in silico docking models that might prove to be effective inhibitors for SARS-CoV-2. Several antiviral medications: Zanamivir, Indinavir, Saquinavir, and Remdesivir show potential as and 3CL(PRO) main proteinase inhibitors and as a treatment for COVID-19. CONCLUSION: Zanamivir, Indinavir, Saquinavir, and Remdesivir are among the exciting hits on the 3CL(PRO) main proteinase. It is also exciting to uncover that Flavin Adenine Dinucleotide (FAD) Adeflavin, B2 deficiency medicine, and Coenzyme A, a coenzyme, may also be potentially used for the treatment of SARS-CoV-2 infections. The use of these off-label medications may be beneficial in the treatment of the COVID-19."],"journal":"Travel Med Infect Dis","authors":["Hall, Donald C Jr","Ji, Hai-Feng"],"date":"2020-04-16T11:00:00Z","year":2020,"_id":"32294562","source":"PubMed","week":"202016|Apr 13 - Apr 19","doi":"10.1016/j.tmaid.2020.101646","keywords":["approved drugs","coronavirus","medications","molecular docking","sars-cov-2"],"e_drugs":["remdesivir","Zanamivir","Flavin-Adenine Dinucleotide","Saquinavir","Indinavir"],"topics":["Treatment","Mechanism"],"weight":1,"_version_":1666138494391549952,"score":180.86674},{"pmid":32442437,"title":"The proteasome as a druggable target with multiple therapeutic potentialities: Cutting and non-cutting edges.","text":["The proteasome as a druggable target with multiple therapeutic potentialities: Cutting and non-cutting edges.","Ubiquitin Proteasome System (UPS) is an adaptable and finely tuned system that sustains proteostasis network under a large variety of physiopathological conditions. Its dysregulation is often associated with the onset and progression of human diseases; hence, UPS modulation has emerged as a promising new avenue for the development of treatments of several relevant pathologies, such as cancer and neurodegeneration. The clinical interest in proteasome inhibition has considerably increased after the FDA approval in 2003 of bortezomib for relapsed/refractory multiple myeloma, which is now used in the front-line setting. Thereafter, two other proteasome inhibitors (carfilzomib and ixazomib), designed to overcome resistance to bortezomib, have been approved for treatment-experienced patients, and a variety of novel inhibitors are currently under preclinical and clinical investigation not only for haematological malignancies but also for solid tumours. However, since UPS collapse leads to toxic misfolded proteins accumulation, proteasome is attracting even more interest as a target for the care of neurodegenerative diseases, which are sustained by UPS impairment. Thus, conceptually, proteasome activation represents an innovative and largely unexplored target for drug development. According to a multidisciplinary approach, spanning from chemistry, biochemistry, molecular biology to pharmacology, this review will summarize the most recent available literature regarding different aspects of proteasome biology, focusing on structure, function and regulation of proteasome in physiological and pathological processes, mostly cancer and neurodegenerative diseases, connecting biochemical features and clinical studies of proteasome targeting drugs.","Pharmacol Ther","Tundo, G R","Sbardella, D","Santoro, A M","Coletta, A","Oddone, F","Grasso, G","Milardi, D","Lacal, P","Marini, S","Purrello, P","Graziani, G","Coletta, M","32442437"],"abstract":["Ubiquitin Proteasome System (UPS) is an adaptable and finely tuned system that sustains proteostasis network under a large variety of physiopathological conditions. Its dysregulation is often associated with the onset and progression of human diseases; hence, UPS modulation has emerged as a promising new avenue for the development of treatments of several relevant pathologies, such as cancer and neurodegeneration. The clinical interest in proteasome inhibition has considerably increased after the FDA approval in 2003 of bortezomib for relapsed/refractory multiple myeloma, which is now used in the front-line setting. Thereafter, two other proteasome inhibitors (carfilzomib and ixazomib), designed to overcome resistance to bortezomib, have been approved for treatment-experienced patients, and a variety of novel inhibitors are currently under preclinical and clinical investigation not only for haematological malignancies but also for solid tumours. However, since UPS collapse leads to toxic misfolded proteins accumulation, proteasome is attracting even more interest as a target for the care of neurodegenerative diseases, which are sustained by UPS impairment. Thus, conceptually, proteasome activation represents an innovative and largely unexplored target for drug development. According to a multidisciplinary approach, spanning from chemistry, biochemistry, molecular biology to pharmacology, this review will summarize the most recent available literature regarding different aspects of proteasome biology, focusing on structure, function and regulation of proteasome in physiological and pathological processes, mostly cancer and neurodegenerative diseases, connecting biochemical features and clinical studies of proteasome targeting drugs."],"journal":"Pharmacol Ther","authors":["Tundo, G R","Sbardella, D","Santoro, A M","Coletta, A","Oddone, F","Grasso, G","Milardi, D","Lacal, P","Marini, S","Purrello, P","Graziani, G","Coletta, M"],"date":"2020-05-23T11:00:00Z","year":2020,"_id":"32442437","source":"PubMed","week":"202021|May 18 - May 24","doi":"10.1016/j.pharmthera.2020.107579","keywords":["cancer","neurodegeneration","proteasome","proteasome inhibitors","sars-cov-2"],"topics":["Mechanism","Treatment"],"weight":1,"_version_":1667523504895950848,"score":165.0853}]}